TYK-ed Off By Rosacea – An Australian Case Series of Rosacea Associated with Deucravacitinib

Deucravacitinib is a novel, oral selective Tyrosine kinase 2 (TYK2) inhibitor used to treat plaque psoriasis. The most common cutaneous adverse effects are acne and folliculitis. However, this report presents seven cases of prototypical papulopustular rosacea (PPR) following the commencement of deucravacitinib. Although most of our patients demonstrated improvement in psoriasis on deucravacitinib, all seven patients discontinued therapy due to the severity and impact of their PPR. Rosacea as an adverse effect of deucravacitinib can be severe, impact on tolerability and influence future treatment options.